|
1
|
Chen QW, Zhu XY, Li YY and Meng ZQ:
Epigenetic regulation and cancer (Review). Oncol Rep. 31:523–532.
2014.PubMed/NCBI
|
|
2
|
Yang Y and Bedford MT: Protein arginine
methyltransferases and cancer. Nat Rev Cancer. 13:37–50. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bedford MT and Clarke SG: Protein arginine
methylation in mammals: Who, what, and why. Mol Cell. 33:1–13.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Krause CD, Yang ZH, Kim YS, Lee JH, Cook
JR and Pestka S: Protein arginine methyltransferases: Evolution and
assessment of their pharmacological and therapeutic potential.
Pharmacol Ther. 113:50–87. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang YC and Li C: Evolutionarily conserved
protein arginine methyltransferases in non-mammalian animal
systems. FEBS J. 279:932–945. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang Y, Hadjikyriacou A, Xia Z, Gayatri S,
Kim D, Zurita-Lopez C, Kelly R, Guo A, Li W, Clarke SG, et al:
PRMT9 is a type II methyltransferase that methylates the splicing
factor SAP145. Nat Commun. 6:64282015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zurita-Lopez CI, Sandberg T, Kelly R and
Clarke SG: Human protein arginine methyltransferase 7 (PRMT7) is a
type III enzyme forming ω-NG-monomethylated arginine residues. J
Biol Chem. 287:7859–7870. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jansson M, Durant ST, Cho EC, Sheahan S,
Edelmann M, Kessler B and La Thangue NB: Arginine methylation
regulates the p53 response. Nat Cell Biol. 10:1431–1439. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Le Romancer M, Treilleux I, Leconte N,
Robin-Lespinasse Y, Sentis S, Bouchekioua-Bouzaghou K, Goddard S,
Gobert-Gosse S and Corbo L: Regulation of estrogen rapid signaling
through arginine methylation by PRMT1. Mol Cell. 31:212–221. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guendel I, Carpio L, Pedati C, Schwartz A,
Teal C, Kashanchi F and Kehn-Hall K: Methylation of the tumor
suppressor protein, BRCA1, influences its transcriptional cofactor
function. PLoS One. 5:e113792010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liao HW, Hsu JM, Xia W, Wang HL, Wang YN,
Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, et al:
PRMT1-mediated methylation of the EGF receptor regulates signaling
and cetuximab response. J Clin Invest. 125:4529–4543. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Auclair Y and Richard S: The role of
arginine methylation in the DNA damage response. DNA Repair (Amst).
12:459–465. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bikkavilli RK, Avasarala S, Vanscoyk M,
Sechler M, Kelley N, Malbon CC and Winn RA: Dishevelled3 is a novel
arginine methyl transferase substrate. Sci Rep. 2:8052012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bikkavilli RK and Malbon CC: Arginine
methylation of G3BP1 in response to Wnt3a regulates β-catenin mRNA.
J Cell Sci. 124:2310–2320. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Blythe SA, Cha SW, Tadjuidje E, Heasman J
and Klein PS: beta-Catenin primes organizer gene expression by
recruiting a histone H3 arginine 8 methyltransferase, Prmt2. Dev
Cell. 19:220–231. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cha B, Kim W, Kim YK, Hwang BN, Park SY,
Yoon JW, Park WS, Cho JW, Bedford MT and Jho EH: Methylation by
protein arginine methyltransferase 1 increases stability of Axin, a
negative regulator of Wnt signaling. Oncogene. 30:2379–2389. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yoshimatsu M, Toyokawa G, Hayami S, Unoki
M, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, et
al: Dysregulation of PRMT1 and PRMT6, Type I arginine
methyltransferases, is involved in various types of human cancers.
Int J Cancer. 128:562–573. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Limm K, Ott C, Wallner S, Mueller DW,
Oefner P, Hellerbrand C and Bosserhoff AK: Deregulation of protein
methylation in melanoma. Eur J Cancer. 49:1305–1313. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Al-Dhaheri M, Wu J, Skliris GP, Li J,
Higashimato K, Wang Y, White KP, Lambert P, Zhu Y, Murphy L, et al:
CARM1 is an important determinant of ERα-dependent breast cancer
cell differentiation and proliferation in breast cancer cells.
Cancer Res. 71:2118–2128. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baldwin RM, Morettin A, Paris G, Goulet I
and Côté J: Alternatively spliced protein arginine
methyltransferase 1 isoform PRMT1v2 promotes the survival and
invasiveness of breast cancer cells. Cell Cycle. 11:4597–4612.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dowhan DH, Harrison MJ, Eriksson NA,
Bailey P, Pearen MA, Fuller PJ, Funder JW, Simpson ER, Leedman PJ,
Tilley WD, et al: Protein arginine methyltransferase 6-dependent
gene expression and splicing: Association with breast cancer
outcomes. Endocr Relat Cancer. 19:509–526. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Goulet I, Gauvin G, Boisvenue S and Côté
J: Alternative splicing yields protein arginine methyltransferase 1
isoforms with distinct activity, substrate specificity, and
subcellular localization. J Biol Chem. 282:33009–33021. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mathioudaki K, Scorilas A, Ardavanis A,
Lymberi P, Tsiambas E, Devetzi M, Apostolaki A and Talieri M:
Clinical evaluation of PRMT1 gene expression in breast cancer.
Tumour Biol. 32:575–582. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim YR, Lee BK, Park RY, Nguyen NT, Bae
JA, Kwon DD and Jung C: Differential CARM1 expression in prostate
and colorectal cancers. BMC Cancer. 10:1972010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Majumder S, Liu Y, Ford OH III, Mohler JL
and Whang YE: Involvement of arginine methyltransferase CARM1 in
androgen receptor function and prostate cancer cell viability.
Prostate. 66:1292–1301. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zakrzewicz D, Zakrzewicz A, Preissner KT,
Markart P and Wygrecka M: Protein arginine methyltransferases
(PRMTs): Promising targets for the treatment of pulmonary
disorders. Int J Mol Sci. 13:12383–12400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mathioudaki K, Papadokostopoulou A,
Scorilas A, Xynopoulos D, Agnanti N and Talieri M: The PRMT1 gene
expression pattern in colon cancer. Br J Cancer. 99:2094–2099.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Papadokostopoulou A, Mathioudaki K,
Scorilas A, Xynopoulos D, Ardavanis A, Kouroumalis E and Talieri M:
Colon cancer and protein arginine methyltransferase 1 gene
expression. Anticancer Res. 29:1361–1366. 2009.PubMed/NCBI
|
|
29
|
Park BJ, Chiosea SI and Grandis JR:
Molecular changes in the multistage pathogenesis of head and neck
cancer. Cancer Biomark. 9:325–339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tang J, Frankel A, Cook RJ, Kim S, Paik
WK, Williams KR, Clarke S and Herschman HR: PRMT1 is the
predominant type I protein arginine methyltransferase in mammalian
cells. J Biol Chem. 275:7723–7730. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Najbauer J and Aswad DW: Diversity of
methyl acceptor proteins in rat pheochromocytoma (PC12) cells
revealed after treatment with adenosine dialdehyde. J Biol Chem.
265:12717–12721. 1990.PubMed/NCBI
|
|
32
|
Najbauer J, Johnson BA and Aswad DW:
Analysis of stable protein methylation in cultured cells. Arch
Biochem Biophys. 293:85–92. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hong S, Heo J, Lee S, Heo S, Kim SS, Lee
YD, Kwon M and Hong S: Methyltransferase-inhibition interferes with
neuronal differentiation of P19 embryonal carcinoma cells. Biochem
Biophys Res Commun. 377:935–940. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yan L, Zhao HY, Zhang Y and Shen YF:
Differential effects of AdOx on gene expression in P19 embryonal
carcinoma cells. BMC Neurosci. 13:62012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim JH, Kim JH, Kim SC, Yi YS, Yang WS,
Yang Y, Kim HG, Lee JY, Kim KH, Yoo BC, et al: Adenosine dialdehyde
suppresses MMP-9-mediated invasion of cancer cells by blocking the
Ras/Raf-1/ERK/AP-1 signaling pathway. Biochem Pharmacol.
86:1285–1300. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim JH, Lee YG, Yoo S, Oh J, Jeong D, Song
WK, Yoo BC, Rhee MH, Park J, Cha SH, et al: Involvement of Src and
the actin cytoskeleton in the antitumorigenic action of adenosine
dialdehyde. Biochem Pharmacol. 85:1042–1056. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schwerk C and Schulze-Osthoff K:
Methyltransferase inhibition induces p53-dependent apoptosis and a
novel form of cell death. Oncogene. 24:7002–7011. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li C, Ai LS, Lin CH, Hsieh M, Li YC and Li
SY: Protein N-arginine methylation in adenosine dialdehyde-treated
lymphoblastoid cells. Arch Biochem Biophys. 351:53–59. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen DH, Wu KT, Hung CJ, Hsieh M and Li C:
Effects of adenosine dialdehyde treatment on in vitro and in vivo
stable protein methylation in HeLa cells. J Biochem. 136:371–376.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hung CJ, Lee YJ, Chen DH and Li C:
Proteomic analysis of methylarginine-containing proteins in HeLa
cells by two-dimensional gel electrophoresis and immunoblotting
with a methylarginine-specific antibody. Protein J. 28:139–147.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Herrmann F, Pably P, Eckerich C, Bedford
MT and Fackelmayer FO: Human protein arginine methyltransferases in
vivo - distinct properties of eight canonical members of the PRMT
family. J Cell Sci. 122:667–677. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Aguirre-Gamboa R, Gomez-Rueda H,
Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R,
Rodriguez-Barrientos A, Tamez-Peña JG and Treviño V: SurvExpress:
An online biomarker validation tool and database for cancer gene
expression data using survival analysis. PLoS One. 8:e742502013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
van Roy F and Berx G: The cell-cell
adhesion molecule E-cadherin. Cell Mol Life Sci. 65:3756–3788.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Perl AK, Wilgenbus P, Dahl U, Semb H and
Christofori G: A causal role for E-cadherin in the transition from
adenoma to carcinoma. Nature. 392:190–193. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li B, Liu L, Li X and Wu L: miR-503
suppresses metastasis of hepatocellular carcinoma cell by targeting
PRMT1. Biochem Biophys Res Commun. 464:982–987. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhou W, Yue H, Li C, Chen H and Yuan Y:
Protein arginine methyltransferase 1 promoted the growth and
migration of cancer cells in esophageal squamous cell carcinoma.
Tumour Biol. 37:2613–2619. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Avasarala S, Van Scoyk M, Rathinam
Karuppusamy MK, Zerayesus S, Zhao X, Zhang W, Pergande MR, Borgia
JA, DeGregori J, Port JD, et al: PRMT1 is a novel regulator of
epithelial-mesenchymal-transition in non-small cell lung cancer. J
Biol Chem. 290:13479–13489. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gao Y, Zhao Y, Zhang J, Lu Y, Liu X, Geng
P, Huang B, Zhang Y and Lu J: The dual function of PRMT1 in
modulating epithelial-mesenchymal transition and cellular
senescence in breast cancer cells through regulation of ZEB1. Sci
Rep. 6:198742016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Altan B, Yokobori T, Ide M, Mochiki E,
Toyomasu Y, Kogure N, Kimura A, Hara K, Bai T, Bao P, et al:
Nuclear PRMT1 expression is associated with poor prognosis and
chemosensitivity in gastric cancer patients. Gastric Cancer.
19:789–797. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
An W, Kim J and Roeder RG: Ordered
cooperative functions of PRMT1, p300, and CARM1 in transcriptional
activation by p53. Cell. 117:735–748. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Reintjes A, Fuchs JE, Kremser L, Lindner
HH, Liedl KR, Huber LA and Valovka T: Asymmetric arginine
dimethylation of RelA provides a repressive mark to modulate
TNFα/NF-κB response. Proc Natl Acad Sci USA. 113:4326–4331. 2016.
View Article : Google Scholar : PubMed/NCBI
|
